Labajo, Erbien G.

HRN: 23-60-66  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/26/2023
AMPICILLIN 500MG (VIAL)
08/26/2023
09/02/2023
IV
280mg
Q6h
AGE
Checking Final Appropriateness 
08/27/2023
METRONIDAZOLE 125MG/5ML, 60ML (BOT)
08/27/2023
09/03/2023
ORAL
3.5ml
TID
Amoebiasis
Waiting Final Action 
08/29/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
08/29/2023
09/07/2023
IV
95mg
Q8
Amoebiasis
Waiting Final Action 
08/29/2023
CEFTRIAXONE 1G (VIAL)
08/29/2023
09/04/2023
IV
230mg
Q12
AGE
Waiting Final Action 
09/02/2023
NYSTATIN 100,000IU/ML, 30ML SUSPENSION (BOT)
09/02/2023
09/07/2023
PO
0.5ml
QID
Pcapc
Waiting Final Action 
09/04/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
09/04/2023
09/10/2023
IV
85mg
Q24h
URTI, AGE With Moderate Dehydration
Waiting Final Action 
09/04/2023
MUPIROCIN 2%, 15G (TUBE)
09/04/2023
09/10/2023
TOPICAL
2%
BID
Infiltrated IV Site
Waiting Final Action 
09/04/2023
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
09/04/2023
09/10/2023
TOPICAL
Apply Thinly
QID
DIAPER RASH
Waiting Final Action 
09/15/2023
CEFTRIAXONE 1G (VIAL)
09/15/2023
09/21/2023
IVT
320mg
Od
Pcap C
Waiting Final Action 
09/15/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
09/15/2023
09/21/2023
IVT
60mg
Od
Pcap C
Waiting Final Action 
09/15/2023
MUPIROCIN 2%, 15G (TUBE)
09/15/2023
09/21/2023
IVT
Bid
Bid
Diaper Rash
Waiting Final Action 
09/16/2023
NYSTATIN 100,000IU/ML, 30ML SUSPENSION (BOT)
09/16/2023
09/23/2023
TOPICAL
0.6ml
QID
Stomatitis
Waiting Final Action 
09/17/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/17/2023
09/23/2023
IV
50mg
Q8
Sepsis, Intraabdominal Infection
Waiting Final Action 
09/17/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
09/17/2023
09/23/2023
IVT
490mg
Q8
Sepsis
Waiting Final Action 
09/18/2023
MUPIROCIN 2%, 15G (TUBE)
09/18/2023
09/25/2023
TOPICAL
2%
BID
Diaper Dermatitis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: